MAFLD
Clinical trials for MAFLD explained in plain language.
Never miss a new study
Get alerted when new MAFLD trials appear
Sign up with your email to follow new studies for MAFLD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gut health and gym: new combo tackles fatty liver
Disease control Not yet recruitingThis study looks at whether combining a probiotic supplement with resistance exercise can help people with metabolic fatty liver disease (MAFLD/NAFLD). Researchers will measure changes in liver fat using MRI over 12 weeks. The goal is to find out which patients benefit most based…
Matched conditions: MAFLD
Phase: NA • Sponsor: Nicolaus Copernicus University • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo pill aims to tackle diabetes and fatty liver at once
Disease control Not yet recruitingThis phase 4 trial will test whether adding alogliptin to a standard two-drug regimen (pioglitazone and metformin) improves blood sugar control and liver health in 80 adults with type 2 diabetes and fatty liver disease. Participants must not have used diabetes medications in the …
Matched conditions: MAFLD
Phase: PHASE4 • Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could a daily pill slow kidney failure in fatty liver patients?
Disease control Not yet recruitingThis study looks at whether oral semaglutide, a drug already used for diabetes, can slow kidney disease in people who also have fatty liver disease. About 90 adults with both conditions will receive either the drug or standard care for 2 years. Researchers will track kidney funct…
Matched conditions: MAFLD
Phase: NA • Sponsor: Institute of Liver and Biliary Sciences, India • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Rhubarb-Derived drug could tackle fatty liver
Disease control Not yet recruitingThis study tests whether diacerein, a drug made from a compound found in rhubarb, can help people with metabolic fatty liver disease. About 74 adults will receive either diacerein or a placebo for 24 weeks. The main goal is to see if the drug reduces fat in the liver, measured by…
Matched conditions: MAFLD
Phase: NA • Sponsor: Hongyan Wu • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Handheld scanner could make liver checks easier
Knowledge-focused Not yet recruitingThis study will compare a new handheld device to the standard iLivTouch system for measuring liver stiffness and fat in 224 adults with chronic liver disease. Participants will be tested with both devices while lying down and sitting. The goal is to see if the handheld device is …
Matched conditions: MAFLD
Sponsor: Hong You • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC